Wyeth, one of the world’s biggest pharmaceutical firms, will use technology from Expression Analysis for clinical trial research, the companies said Wednesday.

Financial details were not disclosed.

The deal comes less than two months after Expression Analysis achieved compliance for Good Laboratory Practices status for supporting clinical trials from the Food and Drug Administration.

The Durham firm, which was launched in 2001, will provide pharmacogenomics testing services through its Affymetrix GeneChip technology for Wyeth.

Expression Analysis uses the principles of semiconductor technology for life sciences, measuring gene expression levels in certain biological organisms.

“Expression Analysis has built its infrastructure to facilitate use of microarray technologies in clinical trials,” said Steve McPhail, president and CEO of Expression Analysis, in a statement. “Executing this agreement with Wyeth, a leader in the field of pharmacogenomics, validates the potential utility of microarray-based gene expression analysis in the clinic.”

Other Expression Analysis clients include Duke University and the EPA.

Expression Analysis: www.expressionanalysis.com